Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm established in 2015 that invests in middle-market companies positioned to benefit from secular industry transformations in China, focusing on New Consumer, Healthcare, and Advanced Manufacturing sectors.
49% of their portfolio is in Biotech & Life Sciences. They made 4 investments in the last 12 months. Average disclosed round size is $107.3M (across 30 rounds with reported amounts).
Portfolio
32
Fund Size
$465M
Top Stage
Series B
Last 12 Mo
4
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
41 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Bristar Immunotech | Series C | — | Jul 2026 |
 YolTech Therapeutics | Series C | $70M | May 2026 |
| YYolTech | Series C | $70M | May 2026 |
| Vvivacta biotechnology | Series A | $50M | Apr 2026 |
 Leads Biolabs | Ipo | — | Jul 2025 |
| MMediLink | Series B | $70M | Apr 2022 |
| MMediLink Therapeutics | Series B | $70M | Mar 2022 |
| DDP Technology | Series B | $100M | Jan 2022 |
 Sciwind | Series C | $70M | Oct 2021 |
 Alebund | Series B | $54.5M | Sep 2021 |
| AAbogen | Series C | $700M | Aug 2021 |
 Edigene | Series B | — | Apr 2021 |
 Immune Onc | Series A | $73M | Mar 2021 |
| MMediLink | Series A | — | Mar 2021 |
 Regor Therapeutics | Series B | $90M | Feb 2021 |
| RRegor | Series B | $90M | Feb 2021 |
| AAbclonal | Series C | $92.9M | Jan 2021 |
| Leads Biolabs | Series C | — | Jan 2021 |
 RemeGen | Growth | $100M | Apr 2020 |
| AAkeso | Series D | $150M | Nov 2019 |
 Genecast | Series D | — | Oct 2019 |
| KKaishu Jianggushi | Series C | $66M | Jul 2019 |
 Zhaoke Ophthalmology | Series A | $50M | Jan 2019 |
| Immune Onc | Series B | $33M | Sep 2018 |
| Genecast | Series C | — | Jan 2018 |
Page 1 of 2
Top Co-Investors
OrbiMed5 shared
LAV4 shared
Vivo Capital4 shared
LYFE Capital4 shared
Lake Bleu Capital3 shared
IDG Capital3 shared
Trustbridge Partners3 shared
Apricot Capital3 shared
Hudson Bay Capital Management2 shared
HighLight Capital2 shared
Legend Capital2 shared
GL Ventures2 shared
Summer Capital2 shared
Sherpa Healthcare Partners2 shared
Northern Light Venture Capital2 shared
Hankang Capital2 shared
Decheng Capital2 shared
C&D Emerging Industry Equity Investment2 shared
Sinovation Ventures2 shared
Last updated: 8 September 2026